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Vertebrobasilar infarcts constitute about 25% of
all cerebral infarcts.1,2 Vertebral artery (VA) stenosis
decreases posterior brain perfusion, causing ver-
tebrobasilar insufficiency (VBI). It is also an im-
portant embolic source for the posterior brain.3–5
Following vertebrobasilar transient ischemic at-
tack (TIA) or stroke, the risk for future stroke over
5 years is 22–35%.6,7 The most frequently involved
location of VA stenosis is the ostium.8 Various
surgical procedures have been described for the
treatment of VA ostial stenosis, but all are techni-
cally difficult with high operative mortality and
morbidity.9,10
Percutaneous angioplasty with or without stent
placement is an alternative treatment for VA ostial
stenosis, with a high success rate and good initial
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ORIGINAL ARTICLE
angiographic outcome. However, the restenosis
rates of balloon angioplasty reported in the liter-
ature were very high, up to 75–100% in 1 year.11–15
Although stenting reduces procedural complica-
tions by offering salvage for unsuccessful balloon
dilatation or dissection, the in-stent restenosis (ISR)
rates were still high, ranging from 10% to 43%.16–19
Recently, site-specific delivery of a cell-cycle in-
hibitor shows promise in inhibiting neointimal
hyperplasia.20 Polymer-based drug-eluting stents
(DES) have been shown to be safe and effective
in reducing ISR in coronary arteries.21,22 Its usage
in the VA orifice, however, is still unproven. The
experience of DES in VA is particularly limited 
in Asians, with only one case reported.23 Here, we
report our results of VA ostial stenting using DES.
Methods
Study design and patient population
With the approval of our institutional review
board, a retrospective review of medical and ra-
diologic records was performed to identify patients
referred to our center for endovascular treatment
of symptomatic ostial VA stenosis refractory to ad-
equate medication. Only patients receiving DES
were included in this study. From October 2004
to September 2006, there were 11 patients who
underwent VA ostial stenting with DES. All patients
presented with typical VBI symptoms, such as se-
vere dizziness, vertigo, or gait disturbance, which
was confirmed by a neurologist. Informed con-
sent was obtained from every patient prior to the
procedures, including follow-up angiography.
Angiography and stenting
Bilateral subclavian and nonselective vertebral
artery angiograms were obtained with a 6F JR4
diagnostic catheter to visualize the true vertebral
ostium, usually at a shallow contralateral cranial
angle. Intracranial continuation to the basilar artery
was also confirmed. Measurements included di-
ameter stenosis (DS), vessel reference diameter
(RD), and lesion length. The diameter of a normal
ipsilateral V2 segment was used as reference, similar
to the NASCET (North American Symptomatic
Carotid Endarterectomy Trial) method for internal
carotid artery stenosis measurement.24
The indications for stenting were pre-specified
as: (a) lesion DS > 75% in a VA with RD > 3.5 mm;
or (b) DS > 50% in a single existing VA with RD
> 3 mm. Lesions of an artery without continuation
to the basilar artery or with severe stenosis beyond
the V2 segment were excluded. Patients with severe
stenosis in the basilar artery or its major branches
were also excluded.
Procedural heparin 70 U/kg was given, and
activated clotting time was kept at 250–300 sec-
onds. A 6F JR4 guiding catheter was placed via 
a femoral sheath into the proximal subclavian
artery without engaging the vertebral ostium. A
0.014 inch coronary angioplasty guide wire was
carefully passed across the stenosis into the distal
cervical vertebral artery. A paclitaxel-eluting stent
(PES) (Taxus, Boston Scientific) or sirolimus-
eluting stent (SES) (Cypher, Cordis Johnson &
Johnson) was then positioned at the ostium and
deployed at high pressure, with diameter matched
to RD. The choice of PES or SES was left to the
operator’s discretion, mainly based on lesion and
vessel characteristics. The goal was to achieve resid-
ual DS < 20%, with complete lesion coverage. All
patients were given aspirin 100 mg and clopidogrel
75mg per day for 7 days before the procedure. After
the procedure, aspirin 100 mg per day was given
indefinitely. Clopidogrel 75 mg per day was given
for 3 months for SES, and 6 months for PES.
Follow-up
All patients were followed with monthly clinic
visits for symptoms and neurologic examination.
If new posterior stroke was suspected, computed
tomography or magnetic resonance imaging was
arranged for documentation. Recurrent VBI symp-
toms were carefully recorded and validated by
neurologists. If restenosis was suspected, angiog-
raphy was mandated to confirm the diagnosis. Ver-
tebral angiogram was also obtained in patients
undergoing angiographic work-up or intervention
for other vascular territories, but no systematic an-
giographic follow-up was planned in the protocol.
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Significant ISR was defined as DS > 50% within
the stented segment.
Statistical analysis
All continuous data were expressed as mean ±
standard deviation. Comparison between pre-
procedure and post-procedure DS was made by
using the paired t test.
Results
The demographics of the 11 patients are summa-
rized in Table 1. The patients were 72 ± 11 years
old, and nine were male. The qualifying symptoms
included severe dizziness (n = 6), gait disturbance
(n=1), syncope (n=2), and posterior fossa strokes
(n = 2). One patient had bilateral VA stenosis, six
had concomitant coronary artery disease, and five
had carotid artery disease. Among patients with
carotid artery disease, two had a past history of
nasopharyngeal cancer with radiotherapy.
The technical success rate was 100%. No peri-
procedural death, stroke, or TIA occurred. No
vascular or other medical complications were
recorded. Angiographic measurements are sum-
marized in Table 2. All 11 patients received direct
stenting without pre-dilatation. Eight PES and
three SES were used. The DS was reduced signifi-
cantly after stenting (86 ± 5 to 2 ± 4%; p < 0.001).
The Figure shows the angiographic picture of a
typical case.
All patients completed the scheduled follow-
up, and remained asymptomatic with a mean
follow-up time of 18.7 ± 8.6 months (range, 6–30
months). Two patients received repeat angiography
at 4 and 8 months after stenting during coronary
intervention procedures, and no significant ISR
was found.
Discussion
VA stenosis occurs primarily at the ostium of the
vessel, and the lesion length and RD are usually
6 mm and 4 mm.23,25 From the experience in coro-
nary stenting, one would expect a single-digit ISR
rate in the VA ostium.26 However, in previous re-
ports using bare metal stents, the ISR rates were
rather high, ranging from 10% to 43%.16,17,19
Therefore, ISR remains a major challenge for VA
ostial stenting despite the high procedural success
and low complication rates.
Recently, DES has been shown to be safe and
effective in reducing ISR in coronary stenting.20,21
The SES has also been shown to reduce the pro-
liferation of smooth muscle cells in a canine basilar
artery model.27 These findings imply that DES may
provide the solution to the high ISR rate in VA
stenting. However, clinical experience of DES on
VA is limited, and has mostly been reported in
Caucasians.28,29 To the best of our knowledge,
only one Asian patient has been reported to 
have received a DES in VA.23 Our report is the
Drug-eluting stent at VA origin
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Table 1. Characteristics of 11 patients
n (%)
Men 9 (82)
Mean age (yr) 72
Hypertension 10 (91)
Diabetes 3 (27)
Hyperlipidemia 3 (27)
Smoking 4 (36)
Bilateral disease 1 (9)
Coronary artery disease 6 (55)
Carotid disease 5 (45)
Previous posterior stroke 2 (18)
Table 2. Angiographic measurements in 11 patients
n (%)
Location, right/left 8/3 (63/27)
Reference diameter (mm) 3.4 ± 0.2
Lesion length (mm) 7.8 ± 4.6
Diameter stenosis (%) 86 ± 5
Stent type, SES/PES 3/8 (27/63)
Stent diameter (mm) 3.4 ± 0.2
Stent length (mm) 13.4 ± 4.6
Maximal deployment 19 ± 4
pressure (atm)
Residual stenosis (%) 2 ± 4
SES = sirolimus-eluting stent; PES = paclitaxel-eluting stent.
first case series of DES implantation at the VA 
ostium in a pure Asian cohort, and demonstrates
that VA stenting with DES is safe and effective 
in Asians.
Lugmayr et al reported the first human series of
SES implantation for the treatment of extracranial
VA stenosis.28 However, the 6-month ISR rate was
surprisingly high (62.5%). Later, Gupta et al re-
ported another series of DES implantation for the
treatment of 62 intracranial or extracranial athero-
sclerotic lesions.29 In that study, 31 (50%) patients
had extracranial VA lesions, but details regarding
stent type or actual implantation position in the VA
were not available. In total, SES was placed in 16
lesions (26%), and PES in 46 (74%). The ISR rate
was 6% with a median follow up time of 4 months
in the entire cohort, and 7% for the extracranial VA
lesions. The ISR rate was similar to coronary ostial
stenting using DES.30 In our series, only two pa-
tients had angiographic follow-up during coronary
intervention. Both patients received PES, and no
ISR was noted. The difference in ISR rates between
studies needs further evaluation.
Chronic stent recoil may also play a role in ISR
of the VA ostium. The VA origin is rich in dense
adventitia, with thick collagen and elastic fibers
around the VA ostium branching from the sub-
clavian artery.31 Metallic stent struts may overcome
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Figure. (A) Angiogram showing a 10-mm long 80%-diameter stenosis at the orifice of the left vertebral artery with 
reference diameter of 3.5 mm. (B) Direct stenting with a 3.5 × 12 mm paclitaxel-eluting stent (maximal pressure, 20 atm).
(C) Final appearance of the vessel after stenting showing 0% residual stenosis. (D) Follow-up angiogram at 8 months
showing no significant in-stent restenosis.
the recoiling force of a non-ostial vessel segment,
and the main factor responsible for ISR is neoin-
timal proliferation.32,33 In aorto-ostial lesions such
as in the right coronary artery ostium, chronic stent
recoil has been shown to contribute significantly
to ISR.34 The same may also occur in the VA ostium.
The highly elastic VA ostial lesions require robust
stent design with a strong radial force. In a recent
study, newly designed balloon-expandable stents
(Neurolink, Guidant) were used in VA and intracra-
nial arterial stenosis.35 To increase its deliverabil-
ity through the tortuous intracranial vessels, the
stent was designed with fewer connecting links.
Although this design increased stent flexibility, it
also decreased the radial force and the scaffold-
ing ability. Although the ISR rate in intracranial
vessels was acceptable, the 6-month ISR rate was
very high in the VA ostium (66.7%). Therefore, we
believed the highly elastic VA ostial lesions re-
quired a stent design with sufficient radial force to
overcome the strong recoiling force, like coronary
stents.
Late stent thrombosis of DES is an important
safety issue. Although the DES is proven to de-
crease ISR and re-intervention by retarding smooth
muscle cell proliferation and extracellular matrix
production, it also delays endothelial healing and
increases the risk of subsequent thrombosis.36,37
In a recent study, use of DES is an independent
risk factor for very late stent thrombosis (6 months
to 3 years) in the coronary artery.38 In a large co-
hort of 8146 patients (3823 SES and 4323 PES),
late stent thrombosis (> 30 days) has been found
to occur more frequently with PES (1.8%) than
with SES (1.4%).39 The late thrombosis rate after
VA stenting remains unclear, and has never been
reported before. In our series, no patient developed
thrombosis at a mean follow-up time of 18.7 ± 8.6
months. However, the follow-up duration is short
and the case number is small. Considering the
relatively low incidence of late stent thrombosis,
observations with more patients and a longer
follow-up is mandatory.
In conclusion, our single center experience
demonstrates Asian patients with symptomatic
VA ostial stenosis may be treated safely with DES.
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